# Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT03272802** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Isfahan University of Medical Sciences** · enrollment: 20 (estimated)

## Conditions studied

- Neuromuscular Diseases

## Interventions

- **DRUG:** Edaravone
- **DRUG:** Riluzole

## Key facts

- **NCT ID:** NCT03272802
- **Lead sponsor:** Isfahan University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-16
- **Primary completion:** 2019-03-16
- **Final completion:** 2019-09-16
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03272802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03272802, "Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03272802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*